Henri Roché
- Oncology top 0.2%
- Cancer Treatment and Pharmacology 109
- HER2/EGFR in Cancer Research 60
- Colorectal Cancer Treatments and Studies 16
- PARP inhibition in cancer therapy 16
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies 77
- Dermatology top 0.5%
- Chemotherapy-related skin toxicity 16
-
- Advanced Breast Cancer Therapies 31
- Genetics top 2%
- BRCA gene mutations in cancer 15
- Co-authors
- P. FumoleauPierre KerbratW. EiermannAnthony GonçalvèsJoanne L. BlumMario CamponeHope S. RugoP. Chollet
- Cited by
- OncologyCancer ResearchDermatology
- Journals
- Journal of Clinical Oncology (49 papers)Cancer Research (16 papers)Annals of Oncology (14 papers)
- Partner nations
- FranceUnited StatesSpain
In The Last Decade
Henri Roché
208 papers receiving 8.7k citations
Hit Papers
Peers
Comparison fields: 5 of 125
- Oncology 6.4k
- Cancer Research 3.3k
- Dermatology 628
- Pulmonary and Respiratory Medicine 1.8k
- Genetics 514
Countries citing papers authored by Henri Roché
This map shows the geographic impact of Henri Roché's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henri Roché with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henri Roché more than expected).
Fields of papers citing papers by Henri Roché
This network shows the impact of papers produced by Henri Roché. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henri Roché. The network helps show where Henri Roché may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Henri Roché, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialbreakdown → | 2020 | 252 |
| 2 | 2019 | 18 | |
| 3 | Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutationbreakdown → | 2018 | 1401 |
| 4 | 2018 | 40 | |
| 5 | 2016 | 15 | |
| 6 | 2015 | 13 | |
| 7 | 2014 | 17 | |
| 8 | 2013 | 31 | |
| 9 | 2012 | 113 | |
| 10 | 2011 | 187 | |
| 11 | 2010 | 21 | |
| 12 | 2010 | 54 | |
| 13 | 2010 | 13 | |
| 14 | 2009 | 208 | |
| 15 | 2009 | 13 | |
| 16 | 2006 | 48 | |
| 17 | [Dose density and dose intensity in the treatment of breast cancer]. | 2004 | 4 |
| 18 | La chimioprévention du cancer du sein | 1998 | 1 |
| 19 | 1996 | 207 | |
| 20 | 1996 | 42 |
About Henri Roché
Henri Roché is a scholar working on Oncology, Cancer Research, Dermatology, Genetics and Pulmonary and Respiratory Medicine, having authored 213 papers that have together received 9.0k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (109 papers), Breast Cancer Treatment Studies (77 papers), HER2/EGFR in Cancer Research (60 papers), Advanced Breast Cancer Therapies (31 papers), Chemotherapy-related skin toxicity (16 papers), Colorectal Cancer Treatments and Studies (16 papers), PARP inhibition in cancer therapy (16 papers) and BRCA gene mutations in cancer (15 papers). The work is most often cited by research in Oncology (6.4k citations), Cancer Research (3.3k citations), Dermatology (628 citations), Pulmonary and Respiratory Medicine (1.8k citations) and Genetics (514 citations). Henri Roché has collaborated with scholars based in France, United States and Spain. Frequent co-authors include P. Fumoleau, Pierre Kerbrat, W. Eiermann, Anthony Gonçalvès, Joanne L. Blum, Mario Campone, Hope S. Rugo, P. Chollet, Sara A. Hurvitz and Jennifer K. Litton. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, European Journal of Cancer and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.